AN2 Therapeutics shareholders elect directors, ratify PwC, approve officer exculpation amendment at 2024 annual meeting

AN2 Therapeutics, Inc.

78.31% quorum with 23,360,239 shares represented; all three Class II director nominees elected.
Margaret FitzPatrick, Patricia Martin, Melvin Spigelman each received over 17.7M votes for.
PricewaterhouseCoopers LLP ratified as auditor: 23,344,330 for, 12,786 against.
Amendment to certificate of incorporation for officer exculpation approved: 18,416,318 for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.